2008: Sjogren's Syndrome

Sjogren's Syndrome

Tuesday, October 28, 2008

1676

Chronic And Insidious Evolution Of Pulmonary Involvement In Primary Sjögren Syndrome: Analysis Of 61 Patients

1677

Central Nervous System Involvement In Patients With Primary Sjögren Syndrome: A Retrospective Study In A Large Cohort Of Italian Patients

1678

Autoantibodies Against Aquaporins in primary Sjögren’s Syndrome (pSS)

1679

Dysautonomia in Primary Sjogren’s Syndrome (pSS) Patients as Assessed in the Outpatient Setting Using Real-Time Digital Autonomic Nervous System Monitoring

1680

Early Small Fiber Sensory Involvement In Asymptomatic Patients With Primary Sjögren Syndrome: A Follow-up Study

1681

Quality of Life, Employment and Disability in Patients with Sjögren’s Syndrome

1682

Relationship between Subjective Cognitive Function and Cognitive Performance in Patients with PSS

1684

SICCA-International Sjögren’s Syndrome Registry: Two Year Follow-up Analyses and Elucidation of Two Keratoconjunctivitis Sicca Subtypes

1685

Secondary Sjögren’s Syndrome in Systemic Lupus Erythematosus Defines a Distinct Disease Subset

1686

Utility of Salivary Scintigraphy to Monitor Treatment of Sjögren’s Syndrome (SS) Using Rituximab

1687

Development Of Liquid Phase Radioimmunoprecipitation Assays For The Detection Of Major And Minor Autoantigens In Primary Sjögren’s Syndrome (pss). Sensitivity, Specificity And Comparison With Elisa And Counterimmunoelectrophoresis (cie)

1688

Association of BLK with Sjögren's Syndrome (SS) and Systemic Lupus Erythematosus (SLE) initially identified by whole genome DNA pooling

1689

Association Of The CGGGG Insertion-deletion Polymorphism Of IRF-5 Gene Promoter With Primary SjöGren’S Syndrome

1690

Functional Polymorphisms Of The P2x₇ Gene Influence Susceptibility To Ro/la Autoantibody-positive Primary Sjögren’s Syndrome

1691

Loss of Salivary Gland Function through Activation of Innate Immunity

1692

Inflammatory Cells at the Autoimmune Minor Salivary Gland (MSG) Lesions of Sjögren’s Syndrome (SS): Differential Distribution depending on Lesion Severity and Correlation with Adverse Prognostic Factors

1693

T Regulatory Cells In Sjögren’s Syndrome (SS) Patients And Their Modulation By Peptides Mapping To The La/SSB Autoantigen

1694

Despite Increased Numbers of IL-7Rnegative-FoxP3-expressing T Cells, IL-7-induced Immune Activation is not Prevented in Patients with Sjögren's Syndrome

1695

Clinical Efficacy of Leflunomide in the Treatment of Primary Sjögren’s Syndrome is Associated with Regulation of T Cell Produced TNFα and IFNγ

1696

Patients With Primary Sjögren’s Syndrome Show A Distinctive Pattern Of Proinflammatory And Immune Cytokines In Function Of The Presence Or Absence Of Anti-ro Autoantibodies

1697

Adiponectin Inhibits Proliferation And Protects Human Non-neoplastic Salivary Gland Epithelial Cells From Spontaneous Apoptosis

1698

The Pathogenesis of Anti-M3 Muscarinic Acetylcholine Receptor Antibodies in Patients with Sjögren’s Syndrome

1699

Functional Autoantibodies in Primary Sjögren’s Syndrome Disrupt GI Tract Motility by Targeting M3 Receptors

1700

Establishment Of New Murine Model For Sjogren’S Syndrome Using M3 Muscarinic Acethylcholine Receptor Knockout Mice

1701

Inhibition Of Experimental Sjögren’s Syndrome Through Immunization with Heat-Shock Protein 60kDa and its Peptide aa437-460

1702

Gender Specific Sjögren's Syndrome Like Salivary Gland Dysfunction after IL-12 Overexpression in Mice

1703

Salivary Gland Interstitial Fluid Cytokines In NOD Mice

1704

IL-6-Dependent Features of Sjogren's Syndrome in B6.Sle1yaa Mice

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>